» Authors » Nelia P Manamela

Nelia P Manamela

Explore the profile of Nelia P Manamela including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 329
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Jamieson P, Shen X, Abu-Shmais A, Wasdin P, Janowska K, Edwards R, et al.
bioRxiv . 2025 Feb; PMID: 39896680
HIV-1 continues to pose a significant global health challenge, requiring ongoing research into effective prevention and treatment strategies. Understanding the B cell repertoire that can be engaged upon vaccination in...
2.
Johnson N, Wall S, Kramer K, Holt C, Periasamy S, Richardson S, et al.
Structure . 2024 Sep; 32(11):1893-1909.e11. PMID: 39326419
The continued emergence of deadly human coronaviruses from animal reservoirs highlights the need for pan-coronavirus interventions for effective pandemic preparedness. Here, using linking B cell receptor to antigen specificity through...
3.
Vukovich M, Shiakolas A, Lindenberger J, Richardson R, Bass L, Barr M, et al.
PLoS Pathog . 2024 Sep; 20(9):e1012499. PMID: 39292703
Broadly reactive antibodies that target sequence-diverse antigens are of interest for vaccine design and monoclonal antibody therapeutic development because they can protect against multiple strains of a virus and provide...
4.
Richardson S, Mzindle N, Motlou T, Manamela N, van der Mescht M, Lambson B, et al.
J Virol . 2024 Jul; 98(7):e0067824. PMID: 38953380
Importance: The continued evolution of SARS-CoV-2 has resulted in a number of variants of concern. Of these, the Omicron sublineage is the most immune evasive. Within Omicron, the BA.4/5 sublineage...
5.
Moyo-Gwete T, Ayres F, Mzindle N, Makhado Z, Manamela N, Richardson S, et al.
Sci Rep . 2024 Jun; 14(1):13311. PMID: 38858452
African Green (Vervet) monkeys have been extensively studied to understand the pathogenesis of infectious diseases. Using vervet monkeys as pre-clinical models may be an attractive option for low-resourced areas as...
6.
Riou C, Bhiman J, Ganga Y, Sawry S, Ayres F, Baguma R, et al.
PLOS Glob Public Health . 2024 Apr; 4(4):e0002703. PMID: 38603677
We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of...
7.
Butters C, Benede N, Moyo-Gwete T, Richardson S, Rohlwink U, Shey M, et al.
Clin Immunol . 2023 Dec; 259:109877. PMID: 38141746
Multisystem inflammatory syndrome in children (MIS-C) is a severe, hyperinflammatory disease that occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The underlying immune pathology of MIS-C is...
8.
Vukovich M, Raju N, Kgagudi P, Manamela N, Abu-Shmais A, Gripenstraw K, et al.
J Virol . 2023 Dec; 98(1):e0147823. PMID: 38085509
Consistent elicitation of serum antibody responses that neutralize diverse clades of HIV-1 remains a primary goal of HIV-1 vaccine research. Prior work has defined key features of soluble HIV-1 Envelope...
9.
Riou C, Bhiman J, Ganga Y, Sawry S, Ayres F, Baguma R, et al.
medRxiv . 2023 Dec; PMID: 38045321
Background: We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose...
10.
Moyo-Gwete T, Richardson S, Keeton R, Hermanus T, Spencer H, Manamela N, et al.
PLoS Pathog . 2023 Nov; 19(11):e1011772. PMID: 37943890
The impact of previous SARS-CoV-2 infection on the durability of Ad26.COV2.S vaccine-elicited responses, and the effect of homologous boosting has not been well explored. We followed a cohort of healthcare...